Effect and Prognosis of Immunohistochemical Biomarkers Changes in Patients With Bladder Cancer After Neoadjuvant Chemotherapy

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University0 sites60 target enrollmentSeptember 1, 2021

ConditionsBladder Cancer

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Bladder Cancer
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Enrollment: 60
Primary Endpoint: Tumor regression grade
Last Updated: 4 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

Clinical trial to investigate the relationship between the expression of immunohistochemical biomarkers GATA-3, CK20, P53 and Ki67 in bladder cancer and pathological complete response after neoadjuvant chemotherapy.

Detailed Description

This is a retrospective study included bladder cancer patients treated with neoadjuvant chemotherapy. We analyzed the changes in the expression of GATA-3, CK20, P53 and Ki67 before and after NAC. Evaluating the sensitivity factor for predicting pathological complete response.

Registry

clinicaltrials.gov

Start Date

September 1, 2021

End Date

August 31, 2022

Last Updated

4 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Any male or female patient aged 18 or older.
•Histologically confirmed bladder cancer, cystectomy was performed after NAC.
•Complete clinical data.

Exclusion Criteria

•Patients with severe organic disease who can not tolerate chemotherapy or surgery
•Patients received previous treatment (chemotherapy, radiation, or molecular targeted therapy).
•Patients with distant metastasis or other cancer history.